Beta Drugs Secures INR 117 Cr Investment to Fuel Oncology Growth

Beta Drugs exports to over 46 countries and holds accreditations from key regulatory bodies, including ANVISA Brazil, INVIMA, PICS, and EAEU.

Beta Drugs, a Himachal Pradesh-based oncology-focused pharmaceutical startup, has raised INR 117 Cr in primary capital from HealthQuad Fund II, alongside a Singapore-based investment fund and a private wealth management firm.

The funding is for a minority stake in the startup, signaling robust investor confidence in Beta Drugs’ vision and capabilities.

HealthQuad, India’s largest healthcare transformation fund, supports innovative healthcare models to enhance accessibility, affordability, and quality of care.

The investment aims to accelerate Beta Drugs’ growth and solidify its position as one of India’s leading oncology companies.

Beta Drugs' Global Reach & Accreditation

Beta Drugs is one of the few vertically integrated oncology manufacturers in India, with a strong presence in both domestic and international markets.

The company exports to over 46 countries and holds accreditations from key regulatory bodies, including ANVISA Brazil, INVIMA, PICS, and EAEU.

Rahul Batra, Chairman and Managing Director of Beta Drugs, expressed confidence in the partnership with HealthQuad.

“HealthQuad's investment and expertise will accelerate our journey to become one of India’s top five oncology companies in the next five years. Leveraging their global network and industry knowledge, we aim to drive innovation, expand our reach, and improve patient care,” he said.

Ajay Mahipal, Partner at HealthQuad Capital, highlighted the alignment between HealthQuad’s mission and Beta Drugs’ focus on oncology.

“Beta Drugs’ manufacturing and R&D capabilities make it a key player in improving affordability and accessibility, especially in tier-II and tier-III cities. The company’s new product launches and expanding export markets position it for significant growth and value creation,” he added.

HealthQuad manages over $200 million across two funds and is currently deploying capital from its second fund, with a corpus of $162 million.

The firm is actively exploring monetization opportunities for two additional companies and plans to initiate the exit process for another company next year.

The Delhi-based VC firm has invested in Qure.ai, ekincare, Red.health, Redcliffe Lifesciences, Wysa, GoApptiv, CureSkin, ImpactGuru, BeatO, and HealthifyMe through its second fund.

Its maiden fund supported investments in hospital chain Regency Health, biotech company Strand Life Sciences, the Asian Institute of Nephrology and Urology (AINU), medical supplies platform Medikabazaar, clinical data aggregation platform THB, telemedicine provider Neurosynaptic Communications, and healthcare staffing company Hi-impact Consultants.

Stay tuned for more such updates on Digital Health News.